Clinical trial · Interventional
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
NCT03123484CI-TRIAL-00027110unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epidermal Growth Factor Receptor tyrosine-kinase inhibitors （EGFR-TKIs）, including gefitinib，erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) | Drug | — | UNRESOLVED |
| β-elemene | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- β-elemene+EGFR TKI
- description
- EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
- interventionNames
- Drug: β-elemene
- Drug: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
- type
- ACTIVE_COMPARATOR
- label
- EGFR TKI
- description
- EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
- interventionNames
- Drug: EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
Primary outcomes (1)
- measure
- PFS ratio in 12 week
- timeFrame
- 12 week
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Obtain of informed consent. 2. Histologically or cytologically confirmed, inoperable, recurrence or metastasis advanced non-small cell lung cancer (TNM Stage ⅢB or stage Ⅳ), took EGFR-TKI longer than 6 months and appeared disease progression. 3. At least one measurable lesion (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response Evaluation Criteria In Solid Tumors（RESCIST） version 1.1). 4. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2. 5. Aged from 18 to 75 years (18 and 75 years are included). 6. Life expectancy ≥12 weeks. 7. Adequate bone marrow reserve and organ function as follows: Absolute neutrophils count (ANC) ≥1.5 x 10 to the 9th power/L (band neutrophil and segmented neutrophil), platelets \> 100 x 10 to the 9th power/L and Hb≥90g/L. Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN). Alkaline phosphatase (AP), alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 3.0 times ULN (or less than or equal to 5 times ULN in case of known liver involvement. Renal: Serum Creatinine less than or equal to 1.25 times upper limit of normal (ULN). 8. Females of child-bearing potential must have negative serum pregnancy test. Sexually active males and females (of childbearing potential) willing to practice contraception during the study. Exclusion Criteria: 1. Do not meet the above criteria. 2. Unhealed toxicity of prior anti-cancer treatment (CTCAE Level 1) or surgery. 3. Symptomatic Central Nervous System (CNS) metastases. 4. Clinical uncontrolled active infection, such as acute pneumonia, active hepatitis B or C (prior hepatitis B history, despite medication treatment control or not, HBV DNA≥500copies or ≥100IU/ml), etc. 5. Prior other malignant disease in 5 years (except carcinoma in situ of cervix, or non melanoma skin cancers, or localized prostate cancer with Gleason ≤6). 6. Take part in new drug clinical trials within one month or taking part in a trial now. 7. Pregnant or lactating woman. 8. Other conditions regimented at investigators' discretion.
References
Publications (5)
- BACKGROUNDXu XW, Yuan ZZ, Hu WH, Wang XK. [Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer]. Zhongguo Zhong Yao Za Zhi. 2013 May;38(9):1430-7. Chinese. PMID 23944083
- BACKGROUNDLi QQ, Wang G, Huang F, Li JM, Cuff CF, Reed E. Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of beta-elemene and its synthetic analogs. Med Oncol. 2013 Mar;30(1):488. doi: 10.1007/s12032-013-0488-9. Epub 2013 Feb 9. PMID 23397083
- BACKGROUNDLiu J, Hu XJ, Jin B, Qu XJ, Hou KZ, Liu YP. beta-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells. J Pharm Pharmacol. 2012 Jan;64(1):146-53. doi: 10.1111/j.2042-7158.2011.01371.x. Epub 2011 Oct 27. PMID 22150682
- BACKGROUNDMatsuoka H, Kaneda H, Sakai K, Koyama A, Nishio K, Nakagawa K. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Clin Lung Cancer. 2017 Jan;18(1):e85-e87. doi: 10.1016/j.cllc.2016.08.004. Epub 2016 Oct 4. No abstract available. PMID 28341110
- BACKGROUNDPassiglia F, Listi A, Castiglia M, Perez A, Rizzo S, Bazan V, Russo A. EGFR inhibition in NSCLC: New findings.... and opened questions? Crit Rev Oncol Hematol. 2017 Apr;112:126-135. doi: 10.1016/j.critrevonc.2017.02.009. Epub 2017 Feb 16. PMID 28325254